<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        141-9-16
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2016
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        LUCENTIS 10MG-ML INTRAVITREAL Injection
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        RANIBIZUMAB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        2353.90
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="NOVARTIS Pharma Stein AG" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            NOVARTIS Pharma Stein AG
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 439]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Novartis Saudi Limited
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            NOVARTIS PHARMA AG
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        S01LA04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Lucentis is</strong></p><p>Lucentis is a solution which is injected into the eye. Lucentis belongs to a group of medicines called antineovascularisation agents. It contains the active substance called ranibizumab.</p><p>&nbsp;</p><p><strong>What Lucentis is used for</strong></p><p>Lucentis is used in adults to treat several eye diseases causing vision impairment.</p><p>&nbsp;</p><p>These diseases result from damage to the retina (light-sensitive layer at the back of the eye) caused by:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Growth of leaky, abnormal blood vessels. This is observed in diseases such as age-related macular degeneration (AMD). It may also be associated with choroidal neovascularisation (CNV) due to pathologic myopia (PM), angioid streaks, central serous chorioretinopathy or inflammatory CNV.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Macular oedema (swelling of the centre of the retina). This swelling can be caused by diabetes (a disease called diabetic macular oedema (DME)) or by the blockage of retinal veins of the retina (a disease called retinal vein occlusion (RVO)).</p><p>&nbsp;</p><p><strong>How Lucentis works</strong></p><p>Lucentis specifically recognizes and binds to a protein called human vascular endothelial growth factor A (VEGF-A) present in the eye. In excess, VEGF-A causes abnormal blood vessel growth and swelling in the eye which can lead to impairment of vision in diseases like AMD, PM, CNV, DME or RVO. By binding to VEGF-A, Lucentis can block its actions and prevent this abnormal growth and swelling.</p><p>&nbsp;</p><p>In these diseases, Lucentis can help to stabilize and in many cases improve your vision.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>a. Do not take Lucentis:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are allergic to ranibizumab or any of the other ingredients of this medicine (listed in section&nbsp;6).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have an infection in or around your eye.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have pain or redness (severe intraocular inflammation) in your eye.</p><p>&nbsp;</p><p><strong>b. Take special care Lucentis:</strong></p><p>Talk to your doctor before you are given Lucentis.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lucentis is given as an injection into the eye. Occasionally, an infection in the internal portion of the eye, pain or redness (inflammation), detachment or tear of one of the layers in the back of the eye (retinal detachment or tear and retinal pigment epithelial detachment or tear), or clouding of the lens (cataract) may occur after Lucentis treatment. It is important to identify and treat such an infection or retinal detachment as soon as possible. Please tell your doctor immediately if you develop signs such as eye pain or increased discomfort, worsening eye redness, blurred or decreased vision, an increased number of small particles in your vision or increased sensitivity to light.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In some patients the eye pressure may increase for a short period directly after the injection. This is something you may not notice, therefore your doctor may monitor this after each injection.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inform your doctor if you have a prior history of eye conditions or eye treatments, or if you have had a stroke or experienced transient signs of stroke (weakness or paralysis of limbs or face, difficulty speaking or understanding). This information will be taken into account to evaluate if Lucentis is the appropriate treatment for you.</p><p>&nbsp;</p><p>Please see section&nbsp;4 (&ldquo;Possible side effects&rdquo;) for more detailed information on side effects that could occur during Lucentis therapy.</p><p>&nbsp;</p><p><strong>c. Children and adolescents (below 18&nbsp;years of age)</strong></p><p>The use of Lucentis in children and adolescents has not been established and is therefore not recommended.</p><p>&nbsp;</p><p><strong>d. Taking </strong><strong>other medicines, herbal or dietary supplements</strong></p><p>Tell your doctor if you are using, have recently used or might use any other medicines.</p><p>&nbsp;</p><p><strong>e. Pregnancy and breast-feeding</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Women who could become pregnant must use effective contraception during treatment and for at least three further months after the last injection of Lucentis.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; There is no experience of using Lucentis in pregnant women. Lucentis should not be used during pregnancy unless the potential benefit outweighs the potential risk to the unborn child. If you are pregnant, think you may be pregnant or planning to become pregnant, discuss this with your doctor before treatment with Lucentis.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Small amounts of Lucentis may pass into breast milk, therefore&nbsp;Lucentis is not recommended during breast-feeding because it is not known whether Lucentis passes into human milk. Ask your doctor or pharmacist for advice before Lucentis treatment.</p><p>&nbsp;</p><p><strong>f. Driving and using machines</strong></p><p>After Lucentis treatment you may experience some temporary vision blurring. If this happens, do not drive or use machines until this resolves</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Lucentis is administered as a single injection into your eye by your eye doctor under a local anaesthetic. The usual dose of an injection is 0.05&nbsp;ml (which contains 0.5&nbsp;mg of active substance). The interval between two doses injected into the same eye should be at least four weeks. All injections will be administered by your eye doctor.</p><p>&nbsp;</p><p>Before the injection, your doctor will wash your eye carefully to prevent infection. Your doctor will also give you a local anaesthetic to reduce or prevent any pain you might have with the injection.</p><p>The treatment is started with one injection of Lucentis per month. Your doctor will monitor the condition of your eye and, depending on how you respond to the treatment, will decide if and when you need to receive further treatment.</p><p>&nbsp;</p><p>Detailed instructions for use are given at the end of the leaflet under &ldquo;How to prepare and administer Lucentis&rdquo;.</p><p>&nbsp;</p><p><strong>Elderly (age 65&nbsp;years and over)</strong></p><p>Lucentis can be used for people of 65&nbsp;years of age and over without dose adjustment.</p><p>&nbsp;</p><p><strong>Before stopping Lucentis treatment</strong></p><p>If you are considering stopping Lucentis treatment, please go to your next appointment and discuss this with your doctor. Your doctor will advise you and decide how long you should be treated with Lucentis.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>The side effects associated with the administration of Lucentis are either due to the medicine itself or the injection procedure and mostly affect the eye.</p><p>&nbsp;</p><p>The most serious side effects are described below:</p><p><strong>Common serious side effects</strong> (may affect up to 1 in 10&nbsp;people): Detachment or tear of the layer in the back of the eye (retinal detachment or tear), resulting in flashes of light with floaters progressing to a temporary loss of sight, or a clouding of the lens (cataract).</p><p><strong>Uncommon serious side effects</strong> (may affect up to 1 in 100&nbsp;people): Blindness, infection of the eyeball (endophthalmitis) with inflammation of the inside of the eye.</p><p>&nbsp;</p><p>The symptoms you might experience are pain or increased discomfort in your eye, worsening eye redness, blurred or decreased vision, an increased number of small particles in your vision or increased sensitivity to light. <strong>Please tell your doctor immediately if you develop any of these side effects</strong>.</p><p>&nbsp;</p><p>The most frequently reported side effects are described below:</p><p><strong>Very common side effects</strong> (may affect more than 1 in 10&nbsp;people)</p><p>Visual side effects include: Inflammation of the eye, bleeding in the back of the eye (retinal bleeding), visual disturbances, eye pain, small particles or spots in your vision (floaters), bloodshot eye, eye irritation, a feeling of having something in the eye, increased tear production, inflammation or infection of the eyelid margins, dry eye, redness or itching of the eye and increased eye pressure.</p><p>Non-visual side effects include: Sore throat, nasal congestion, runny nose, headache and joint pain.</p><p>&nbsp;</p><p>Other side effects which may occur following Lucentis treatment are described below:</p><p><strong>Common side effects</strong></p><p>Visual side effects include: Decreased sharpness of vision, swelling of a section of the eye (uvea, cornea), inflammation of the cornea (front part of eye), small marks on the surface of the eye, blurred vision, bleeding at the site of injection, bleeding in the eye, discharge from the eye with itching, redness and swelling (conjunctivitis), light sensitivity, eye discomfort, swelling of the eyelid, eyelid pain.</p><p>Non-visual side effects include: Urinary tract infection, low red blood cells count (with symptoms such as tiredness, breathlessness, dizziness, pale skin), anxiety, cough, nausea, allergic reactions like rash, hives, itching and skin reddening.</p><p>&nbsp;</p><p><strong>Uncommon side effects</strong></p><p>Visual side effects include: Inflammation and bleeding in the front part of the eye, sac of pus on the eye, changes of the central part of the eye surface, pain or irritation at the site of injection, abnormal sensation in the eye, irritation of the eyelid.</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep this medicine out of the sight and reach of children.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine after the expiry date which is stated on the carton and vial label after EXP. The expiry date refers to the last day of that month.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store in a refrigerator (2&deg;C &ndash; 8&deg;C). Do not freeze.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Prior to use, the unopened vial may be kept at room temperature (25&deg;C) for up to 24&nbsp;hours.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep the vial in the outer carton in order to protect from light.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use any pack that is damaged</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ul><li>The active substance is ranibizumab. Each ml contains 10&nbsp;mg ranibizumab. Each vial contains 2.3&nbsp;mg ranibizumab in 0.23&nbsp;ml solution. This provides a suitable amount to deliver a single dose of 0.05&nbsp;ml containing 0.5&nbsp;mg ranibizumab.</li><li>The other ingredients are &alpha;,&alpha;-trehalose dihydrate; histidine hydrochloride, monohydrate; histidine; polysorbate 20; water for injections.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	Lucentis is a solution for injection in a vial (0.23 ml). The solution is clear, colourless to pale yellow and aqueous.
	
Vial + injection kit
	Pack containing one glass vial of ranibizumab with chlorobutyl rubber stopper, one blunt filter needle (18G x 1½″, 1.2 mm x 40 mm, 5 micrometres) for withdrawal of the vial contents, one injection needle (30G x ½″, 0.3 mm x 13 mm) and one syringe (1 ml) for withdrawal of the vial contents and for intravitreal injection. All components are for single use only.

Vial + filter needle pack
	Pack containing one glass vial of ranibizumab with chlorobutyl rubber stopper and one blunt filter needle (18G x 1½″, 1.2 mm x 40 mm, 5 micrometres) for withdrawal of the vial contents. All components are for single use only.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The Marketing Authorization Holder for this Product is Novartis Pharma AG.</p><p>www.Novartis.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                10/2022
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>ما هو لوسينتيس</strong></p><p dir="RTL">عقار لوسنتس عبارة عن محلول يُحقن في العين. ينتمي هذا الدَّواء إلى مجموعة من الأدوية تسمى مضادات التوَعي الحَديث. ويحتوي على مادة فعّالة تُسمى رانيبيزوماب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>فيم يُستخدم </strong><strong>لوسينتيس</strong></p><p dir="RTL">يُستخدم عقار لوسنتس لعلاج البالغين من العديد من أمراض العيون التي تسبب ضعف البصر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تنتج هذه الأمراض عن ضرر يلحق بالشبكية (الطبقة الحساسة للضوء الموجودة في الجانب الخلفي للعين) نتيجة:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نمو أوعية دموية غير طبيعية بها تسرب. ويُلاحظ ذلك في أمراض مثل التنكُّس البقعي المرتبط بالسن واعتلال الشبكية السُّكَّرِي التكاثري (مرض ينجم عن مرض السُّكَّرِي). وقد يكون مقترنًا أيضًا بالتوَعي الحَديث في مشيمية العين (CNV) النَّاتج عن قصر النَّظر المرضي (PM) أو الأَتْلَام وِعائِيَّة الشَّكِل أو اعتلال المشيمية والشبكية المصلي المركزي أو التوَعي الحَديث في مشيمية العين الالتهابي.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الوذمة البقعية (تورُّم مركز الشبكية). قد يكون هذا التورُّم ناجمًا عن مرض السُّكَّرِي (مرض يُسمى الوذمة البقعية السكرية (DME)) أو عن انسداد الأوردة الشبكية في شبكية العين (مرض يُسمى انسداد الوريد الشبكي (RVO)).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كيف يعمل لوسينتيس</strong></p><p dir="RTL">يتعرفعقار لوسنتس تحديدًاعلى بروتين يُسمى عامل نمو بطانة الأوعية الدموية البشري أ (VEGF-A) في العين ويرتبط العقار بهذا البروتين. في حالة وجود عامل نمو بطانة الأوعية الدموية البشري أ هذا بكثرة، يُسبب&nbsp; نموًّا غير طبيعي للأوعية الدموية وتورمًا في العين قد يؤدي إلى ضعف البصر في أمراض مثل التنكُّس البقعي المرتبط بالسن والوذمة البقعية السكرية واعتلال الشبكية السُّكَّرِي التكاثري وانسداد الوريد الشبكي وقصر النَّظر المرضي والتوَعي الحَديث في مشيمية العين. ومن خلال ارتباط عقار لوسنتس بعامل نمو بطانة الأوعية الدموية البشري أ، فإنه يمكن للعقار حجب عمل العامل ومنع حدوث هذا التورُّم والنمو غير الطبيعي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">في هذه الأمراض، يمكن أن يساعد عقار لوسنتس على ثبات الرؤية بل وتحسينها في العديد من الحالات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أ. </strong><strong>موانع استعمال</strong><strong> لوسينتيس</strong></p><p dir="RTL"><strong>يحظر تناول عقار لوسنتس في الحالات الآتية:</strong></p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كانت لديك </strong>حساسية مفرطة تجاه رانيبيزوماب أو تجاه أي من المكونات الأخرى في هذا الدواء (مذكورة في بند 6).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كانت لديك</strong> عدوى في العين أو حولها.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كان لديك</strong> ألم أو احمرار في العين (التهاب شديد في باطن العين).</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>ب. </strong><strong>الاحتياطات عند استعمال </strong><strong>لوسينتيس</strong></p><p dir="RTL">تحدث إلى طبيبك قبل أن يتم إعطاؤك عقار لوسنتس في الحالات الآتية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُعطى عقار لوسنتس في صورة حقن داخل العين. قد تحدث في بعض الأحيان عدوى في الجزء الداخلي من العين أو ألم أو احمرار (التهاب) أو انفصال أو تمزق إحدى الطبقات في الجزء الخلفي من العين (انفصال الشبكية أو تمزقها وانفصال الظهارة الصباغية الشبكية أو تمزقها)، أو إعتام عدسة العين (المياه البيضاء) بعد العلاج بعقار لوسنتس. ومن المهم تحديد هذه العدوى أو انفصال الشبكية وعلاجها بأسرع ما يمكن. يُرجى إخبار طبيبك على الفور إذا ظهرت عليك علامات مثل الألم بالعين أو الانزعاج المتزايد أو تفاقم احمرار العين أو عدم وضوح الرؤية أو انخفاضها أو زيادة عدد الجسيمات الصغيرة في الرؤية أو زيادة الحساسية تجاه الضوء.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يرتفع الضغط داخل العين لدى بعض المرضى لفترة قصيرة بعد الحقن مباشرة. هذا شيء قد لا تلاحظه، وبالتالي قد يراقب طبيبك هذا بعد كل مرة يتم حقنك فيها.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخبر طبيبك إذا كان لديك تاريخ سابق من الإصابة بأمراض في العين أو تتناول علاجات لها، أو إذا كان قد سبق لك أن عانيت من سكتة دماغية أو تعرضت لعلامات السكتة الدماغية العابرة (ضعف أو شلل في الأطراف أو الوجه أو صعوبة في الكلام أو الفهم). وستوضع هذه المعلومات في الاعتبار؛ لتقييم ما إذا كان عقار لوسنتس مناسبًا لك أم لا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُرجى أيضًا النظر إلى القسم: 4 (&quot;الآثار الجانبية المحتملة&quot;)؛ لمعرفة معلومات أكثر تفصيلًا حول الآثار الجانبية التي قد تحدث أثناء العلاج بعقار لوسنتس.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>. الأطفال والمراهقون (تحت 18 سنة من العمر)</strong></p><p dir="RTL">لا يوصى باستخدام عقار لوسنتس للأطفال والمراهقين حيث لم يتم التَّأكد من استخدامه لهم إلا لعلاج اعتلال الشبكية في الأطفال المبتسرين. لعلاج الرُّضع المبتسرين المصابين باعتلال شبكية العين في المبتسرين يُرجى النظر إلى الجانب الآخر من هذه النشرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>جز&nbsp;&nbsp;</strong><strong>التداخلات الدوائية من أخذ هذا المستحضر مع أدوية أخرى أو أعشاب أو مكملات غذائية</strong><strong>:</strong></p><p dir="RTL">يُرجى إبلاغ طبيبك إذا كنت تستخدم أو استخدمت مؤخرًا أو قد تستخدم أيَّة أدوية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>د. </strong><strong>الحمل والرضاعة</strong><strong>:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب على السيدات ممن لديهن القدرة على الحمل استخدام وسيلة منع حمل فعالة أثناء العلاج ولمدة ثلاثة أشهر على الأقل بعد آخر مرة يتم فيها حقن عقار لوسنتس.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تُوجد خبرة بشأن استخدام عقار لوسنتس للحوامل. يجب ألا يتم استخدام عقار لوسنتس أثناء الحمل إلا إذا كانت الفوائد المتوقعة تفوق المخاطر المتوقعة على الجنين. لذا يجب عليكِ مناقشة طبيبك قبل العلاج بعقار لوسنتس إذا كنتِ حاملًا أو تظنين أنك ربما تكونين حاملًا أو تعتزمين الحمل.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تنتقل كميات صغيرة من لوسنتس إلى حليب الثدي، لذلك لا يُوصى بالعلاج بعقار لوسنتس أثناء فترة الإرضاع طبيعيًّا. استشيري طبيبكِ أو الصيدلي الخاص بكِ قبل العلاج بعقار لوسنتس.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>هـ. تأثير عقار لوسنتس على القيادة واستخدام الآلات</strong></p><p dir="RTL">قد تعاني بعد العلاج بعقار لوسنتس من عدم وضوح الرؤية إلى حد ما لفترة مؤقتة. إذا حدث لك هذا، لا تمارس القيادة أو تستخدم أية آلات حتى يزول هذا.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُعطى عقار لوسنتس في صورة حقنة واحدة داخل العين بواسطة طبيب العيون تحت تخدير موضعي. وتبلغ الجرعة الاعتيادية للحقنة 0.05 مللي لتر (تحتوي على 0.5 مجم من المادة الفعَّالة). لا يجب أن يقل الفاصل الزمني بين جرعتي الحقن في العين نفسها عن أربعة أسابيع. وينبغي إعطاء جميع الحقن بواسطة طبيب العيون.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قبل الحقن، سيغسل طبيبك عينك بعناية تفاديًا لإصابتك بالعدوى. كذلك، سيقوم طبيبك بتخديرك موضعيًّا لتقليل أو منع الألم الذي قد يصيبك نتيجة الحقن.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي بدء العلاج بحقنة واحدة من عقار لوسنتس في الشهر. سيراقب طبيبك حالة عينك وسيقرر بناءً على مدى استجابتك للعلاج ما إذا كنت ستحتاج إلى مزيد من العلاج أم لا ومتى ستحتاج إليه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">توجد في نهاية النشرة تعليمات الاستخدام المفصلة تحت عنوان &quot;كيفية تحضير عقار لوسنتس وإعطائه&quot;.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كبار السن (بعمر 65 عامًا فأكبر)</strong></p><p dir="RTL">يمكن استخدام عقار لوسنتس للأشخاص البالغين من العمر 65 عامًا فأكبر دون الحاجة إلى تعديل الجرعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أ&zwnj;.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>التوقف عن تناول عقار لوسنتس</strong></p><p dir="RTL">إذا كنت تفكر في وقف العلاج بعقار لوسنتس، فيرجى الذهاب إلى طبيبك في الموعد التالي ومناقشته بشأن ذلك. سيقدم لك طبيبك المشورة وسيحدد المدة التي ينبغي عليك فيها العلاج بعقار لوسنتس.</p><p dir="RTL">&nbsp;</p><p dir="RTL">اسأل طبيبك في حالة وجود أية أسئلة إضافية متعلقة باستخدام هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثله مثل كافة الأدوية، قد يُسبب هذا الدَّواء آثارًا جانبية، على الرَّغم من عدم حدوثها لدى الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تكون الآثار الجانبية المرتبطة بعقار لوسنتس إما بسبب الدَّواء نفسه أو بسبب إجراء الحقن وتؤثر في الغالب على العين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">فيما يلي الآثار الجانبية الأكثر خطورة:</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الآثار الجانبية الشَّائعة الخطيرة</strong> (قد تُؤثر على ما يصل إلى شخص واحد من بين كل 10&nbsp;أشخاص): انفصال أو تمزق إحدى الطبقات في الجزء الخلفي من العين (انفصال الشبكية أو تمزقها)، مما يؤدي إلى رؤية ومضات أو ضوء به عوائم وقد يتطور الأمر إلى فقدان مؤقت لحاسة البصر، أو إعتام عدسة العين (المياه البيضاء).</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الآثار الجانبية غير الشائعة الخطيرة </strong>(قد تُؤثر على ما يصل إلى شخص واحد من بين كل 100 شخص): فقدان البصر، عدوى في مقلة العين (التهاب باطن المقلة) مع التهاب الجزء الدَّاخلي للعين.</p><p dir="RTL">&nbsp;</p><p>الأعراض التي قد تعاني منها هي الألم بالعين أو الانزعاج المتزايد أو تفاقم احمرار العين أو عدم وضوح الرؤية أو انخفاضها أو زيادة عدد الجسيمات الصغيرة في الرؤية أو زيادة الحساسية تجاه الضوء. <strong>برجاء إخبار طبيبك</strong></p><p dir="RTL"><strong>فورًا إذا تعرضت لأي من الآثار الجانبية الآتية.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">فيما يلي الآثار الجانبية التي تم الإبلاغ عنها بشكل أكثر تكرارًا:</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>آثار جانبية شائعة جدًّا </strong>(قد تُؤثر على أكثر من شخص واحد بين كل 10&nbsp;أشخاص)</p><p dir="RTL">تشمل الآثار الجانبية المتعلقة بالرؤية: التهاب العين ونزيفًا في الجزء الخلفي من العين (نزيفًا من الشبكية) واضطرابات الرؤية وألمًا بالعين ووجود جسيمات صغيرة أو بقع في الرؤية (عوائم) واحتقان العين بالدم وتهيج العين والإحساس بوجود شيء ما بالعين وزيادة إفراز الدموع والتهاب أو عدوى بحواف الجفون وجفاف العين واحمرار العين أو حكة في العين وزيادة ضغط العين.</p><p dir="RTL">تشمل الآثار الجانبية غير المتعلقة بالرؤية: التهاب الحلق واحتقان الأنف وسيلان الأنف والصداع وألم المفاصل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">فيما يلي الآثار الجانبية الأخرى التي قد تحدث بعد العلاج بعقار لوسنتس:</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الآثار الجانبية الشائعة</strong></p><p dir="RTL">تشمل الآثار الجانبية المتعلقة بالرؤية: انخفاض حدة الإبصار، تورم جزء من العين (العنبية، القرنية)، التهاب القرنية (الجزء الأمامي من العين)، ظهور علامات صغيرة على سطح العين، عدم وضوح الرُّؤية، نزيفًا في موضع الحقن، نزيفًا في العين، إفرازات من العين مصحوبة بحكة واحمرار وتورمًا (التهاب المُلْتَحِمَة)، حساسية تجاه الضوء، شعورًا غير مريح بالعين، تورم جفن العين، ألمًا بجفن العين.</p><p dir="RTL">تشمل الآثار الجانبية غير المتعلقة بالرؤية: عدوى المسالك البولية، انخفاض مستوى خلايا الدم الحمراء (مصحوبة بأعراض مثل التعب، عُسْر التَّنَفُّس، الدوخة، شحوب الجلد)، القلق، السعال، الغثيان، تفاعلات الحساسية مثل الطفح جلدي، الشرى (الأرتكاريا)، الحكة، احمرار الجلد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبيَّة غير الشَّائعة</strong></p><p dir="RTL">تشمل الآثار الجانبية المتعلقة بالرؤية: التهابًا ونزيفًا في الجزء الأمامي من العين، تكون أكياس صديد في العين، حدوث تغييرات في الجزء الأوسط من سطح العين، ألمًا أو تهيُّجًا في موضع الحقن، إحساسًا غير طبيعي في العين، تهيُّج جفن العين.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُحفظ هذا الدَّواء بعيدًا عن رؤية ومُتناوَل الأطفال.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستعمل هذا الدَّواء بعد تاريخ انتهاء الصلاحية المدون على ملصق العبوة والزجاجة بعد كلمة EXP. يُشير تاريخ انتهاء الصَّلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ في الثلاجة (عند 2&mdash;8 درجة مئوية). لا تعرضه للتَّجميد.</p><p dir="RTL">يمكن تخزين الزجاجة التي لم يتم فتحها في درجة حرارة الغرفة (25 درجة مئوية) لمدة تصل إلى 24 ساعة قبل الاستخدام</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احتفظ بالزجاجة داخل العبوة الكرتونية الخارجية لحمايتها من الضوء.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم أي عبوة تالفة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي رانيبيزوماب. يحتوي كل مللي لتر على 10 مجم رانيبيزوماب. تحتوي كل زجاجة على 2.3 مجم من رانيبيزوماب في 0.23 مللي لتر من المحلول. وهي توفر كمية مناسبة لإعطاء جرعة واحدة بمقدار 0.05 مللي لتر تحتوي على 0.5 مجم رانيبيزوماب.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي، &alpha;،&alpha;-طِرهالُوز ثنائي الهيدرات، هستيدين هيدروكلوريد، أحادي الهيدرات، هستيدين، بوليسوربات 20، ماء للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">عقار لوسنتس عبارة عن محلول معد للحقن يتوفر في زجاجة (0.23 مللي لتر). المحلول مائي وصافٍ وعديم اللون يميل لونه إلى اللون الأصفر الشاحب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>عبوة تحتوي على زجاجة + إبرة ترشيح</u></p><p dir="RTL">عبوة تحتوي على زجاجة رانيبيزوماب واحدة بها سدادة مطاطية من الكلوروبوتيل وإبرة ترشيح غير حادة واحدة (عيار 18 &times; 1&frac12; بوصة، 1.2 مللي متر &times; 40 مللي متر، 5 ميكرومتر) لسحب محتويات الزجاجة. جميع المكونات للاستخدام مرة واحدة فقط.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مالك حق التسويق لهذا المنتج هي شركة نوفارتس فارما إيه جي.</p><p dir="RTL">www.Novartis.com</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            10/2022
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Lucentis 10 mg/ml solution for injection
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                One ml contains 10 mg ranibizumab*. Each vial contains 2.3 mg of ranibizumab in 0.23 ml solution. This provides a usable amount to deliver a single dose of 0.05 ml containing 0.5 mg ranibizumab.

*Ranibizumab is a humanised monoclonal antibody fragment produced in Escherichia coli cells by recombinant DNA technology.

For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection.

Clear, colourless to pale yellow aqueous solution.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <ul><li>Lucentis is indicated in adults for:</li></ul><ol><li>The treatment of neovascular (wet) age-related macular degeneration (AMD)</li><li>The treatment of visual impairment due to diabetic macular oedema (DME)</li><li>The treatment of proliferative diabetic retinopathy (PDR)</li><li>The treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO)</li><li>The treatment of visual impairment due to choroidal neovascularisation (CNV)</li></ol><p>&nbsp;</p><ul><li>Lucentis is indicated in preterm infants for:</li></ul><ol><li>The treatment of retinopathy of prematurity (ROP) with zone&nbsp;I (stage&nbsp;1+, 2+, 3 or 3+), zone&nbsp;II (stage 3+) or AP-ROP (aggressive posterior ROP) disease.</li></ol><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lucentis must be administered by a qualified ophthalmologist experienced in intravitreal injections.</p><p>&nbsp;</p><p><u>Posology</u></p><p>&nbsp;</p><p><em><u>Adults</u></em></p><p>The recommended dose for Lucentis in adults is 0.5&nbsp;mg given as a single intravitreal injection. This corresponds to an injection volume of 0.05&nbsp;ml. The interval between two doses injected into the same eye should be at least four weeks.</p><p>&nbsp;</p><p>Treatment in adults is initiated with one injection per month until maximum visual acuity is achieved and/or there are no signs of disease activity i.e. no change in visual acuity and in other signs and symptoms of the disease under continued treatment. In patients with wet AMD, DME, PDR and RVO, initially, three or more consecutive, monthly injections may be needed.</p><p>&nbsp;</p><p>Thereafter, monitoring and treatment intervals should be determined by the physician and should be based on disease activity, as assessed by visual acuity and/or anatomical parameters.</p><p>&nbsp;</p><p>If, in the physician&rsquo;s opinion, visual and anatomic parameters indicate that the patient is not benefiting from continued treatment, Lucentis should be discontinued.</p><p>&nbsp;</p><p>Monitoring for disease activity may include clinical examination, functional testing or imaging techniques (e.g. optical coherence tomography or fluorescein angiography).</p><p>&nbsp;</p><p>If patients are being treated according to a treat-and-extend regimen, once maximum visual acuity is achieved and/or there are no signs of disease activity, the treatment intervals can be extended stepwise until signs of disease activity or visual impairment recur. The treatment interval should be extended by no more than two weeks at a time for wet AMD and may be extended by up to one month at a time for DME. For PDR and RVO, treatment intervals may also be gradually extended, however there are insufficient data to conclude on the length of these intervals. If disease activity recurs, the treatment interval should be shortened accordingly.</p><p>&nbsp;</p><p>The treatment of visual impairment due to CNV should be determined individually per patient based on disease activity. Some patients may only need one injection during the first 12&nbsp;months; others may need more frequent treatment, including a monthly injection. For CNV secondary to pathologic myopia (PM), many patients may only need one or two injections during the first year (see section&nbsp;5.1).</p><p>&nbsp;</p><p><em>Lucentis and laser photocoagulation in DME and in macular oedema secondary to BRVO</em></p><p>There is some experience of Lucentis administered concomitantly with laser photocoagulation (see section&nbsp;5.1). When given on the same day, Lucentis should be administered at least 30&nbsp;minutes after laser photocoagulation. Lucentis can be administered in patients who have received previous laser photocoagulation.</p><p>&nbsp;</p><p><em>Lucentis and </em><em>verteporfin</em><em> photodynamic therapy in CNV secondary to PM</em></p><p>There is no experience of concomitant administration of Lucentis and verteporfin.</p><p>&nbsp;</p><p><em><u>Preterm infants</u></em></p><p>The recommended dose for Lucentis in preterm infants is 0.2&nbsp;mg given as an intravitreal injection. This corresponds to an injection volume of 0.02&nbsp;ml. In preterm infants treatment of ROP is initiated with a single injection per eye and may be given bilaterally on the same day. In total, up to three injections per eye may be administered within six months of treatment initiation if there are signs of disease activity. Most patients (78%) in the clinical study received one injection per eye. The administration of more than three injections per eye has not been studied.<strong><u> </u></strong>The interval between two doses injected into the same eye should be at least four weeks.</p><p>&nbsp;</p><p><em><u>Special populations</u></em></p><p><em>Hepatic impairment</em></p><p>Lucentis has not been studied in patients with hepatic impairment. However, no special considerations are needed in this population.</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>Dose adjustment is not needed in patients with renal impairment (see section&nbsp;5.2).</p><p><em>&nbsp;</em></p><p><em>Elderly</em></p><p>No dose adjustment is required in the elderly. There is limited experience in patients older than 75&nbsp;years with DME.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The safety and efficacy of Lucentis in children and adolescents below 18&nbsp;years of age for indications other than retinopathy of prematurity have not been established. Available data in adolescent patients aged 12 to 17&nbsp;years with visual impairment due to CNV are described in section&nbsp;5.1 but no recommendation on a posology can be made.</p><p><u>&nbsp;</u></p><p><u>Method of administration</u></p><p>&nbsp;</p><p>Single-use vial for intravitreal use only.</p><p>&nbsp;</p><p>Since the volume contained in the vial (0.23&nbsp;ml) is greater than the recommended dose (0.05&nbsp;ml for adults and 0.02&nbsp;ml for preterm infants), a portion of the volume contained in the vial must be discarded prior to administration.</p><p>&nbsp;</p><p>Lucentis should be inspected visually for particulate matter and discoloration prior to administration.</p><p>&nbsp;</p><p>For information on preparation of Lucentis, see section&nbsp;6.6.</p><p>&nbsp;</p><p>The injection procedure should be carried out under aseptic conditions, which includes the use of surgical hand disinfection, sterile gloves, a sterile drape and a sterile eyelid speculum (or equivalent) and the availability of sterile paracentesis (if required). The patient&rsquo;s medical history for hypersensitivity reactions should be carefully evaluated prior to performing the intravitreal procedure (see section&nbsp;4.4). Adequate anaesthesia and a broad-spectrum topical microbicide to disinfect the periocular skin, eyelid and ocular surface should be administered prior to the injection, in accordance with local practice.</p><p>&nbsp;</p><p><em><u>Adults</u></em></p><p>In adults the injection needle should be inserted 3.5‑4.0&nbsp;mm posterior to the limbus into the vitreous cavity, avoiding the horizontal meridian and aiming towards the centre of the globe. The injection volume of 0.05&nbsp;ml is then delivered; a different scleral site should be used for subsequent injections.</p><p>&nbsp;</p><p><em><u>Paediatric population</u></em></p><p>For treatment of preterm infants the low volume high accuracy syringe provided together with an injection needle (30G&nbsp;x&nbsp;&frac12;&Prime;) in the VISISURE kit should be used (see also section&nbsp;6.6).</p><p>&nbsp;</p><p>In preterm infants, the injection needle should be inserted into the eye 1.0 to 2.0&nbsp;mm posterior to the limbus, with the needle pointing towards the optic nerve. The injection volume of 0.02&nbsp;ml is then delivered.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Patients with active or suspected ocular or periocular infections.
Patients with active severe intraocular inflammation.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Traceability</u><br />In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.</p><p><u>Intravitreal injection-related reactions</u></p><p>&nbsp;</p><p>Intravitreous injections, including those with Lucentis, have been associated with endophthalmitis, intraocular inflammation, rhegmatogenous retinal detachment, retinal tear and iatrogenic traumatic cataract (see section&nbsp;4.8). Proper aseptic injection techniques must always be used when administering Lucentis. In addition, patients should be monitored during the week following the injection to permit early treatment if an infection occurs. Patients should be instructed to report any symptoms suggestive of endophthalmitis or any of the above mentioned events without delay.</p><p>&nbsp;</p><p><u>Intraocular pressure increases</u></p><p>&nbsp;</p><p>Transient increases in intraocular pressure (IOP) have been seen within 60&nbsp;minutes of injection of Lucentis. Sustained IOP increases have also been identified (see section&nbsp;4.8). Both intraocular pressure and the perfusion of the optic nerve head must be monitored and managed appropriately.</p><p>&nbsp;</p><p>Patients should be informed of the symptoms of these potential adverse reactions and instructed to inform their physician if they develop signs such as eye pain or increased discomfort, worsening eye redness, blurred or decreased vision, an increased number of small particles in their vision, or increased sensitivity to light (see section&nbsp;4.8).</p><p>&nbsp;</p><p><u>Bilateral treatment</u></p><p>&nbsp;</p><p>Limited data on bilateral use of Lucentis (including same-day administration) do not suggest an increased risk of systemic adverse events compared with unilateral treatment.</p><p>&nbsp;</p><p><u>Immunogenicity</u></p><p>&nbsp;</p><p>There is a potential for immunogenicity with Lucentis. Since there is a potential for an increased systemic exposure in subjects with DME, an increased risk for developing hypersensitivity in this patient population cannot be excluded. Patients should also be instructed to report if an intraocular inflammation increases in severity, which may be a clinical sign attributable to intraocular antibody formation.</p><p>&nbsp;</p><p><u>Concomitant use of other anti-VEGF (vascular endothelial growth factor)</u></p><p>&nbsp;</p><p>Lucentis should not be administered concurrently with other anti-VEGF medicinal products (systemic or ocular).</p><p>&nbsp;</p><p><u>Withholding Lucentis</u></p><p>&nbsp;</p><p>The dose should be withheld and treatment should not be resumed earlier than the next scheduled treatment in the event of:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a decrease in best-corrected visual acuity (BCVA) of &ge;30&nbsp;letters compared with the last assessment of visual acuity;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an intraocular pressure of &ge;30&nbsp;mmHg;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a retinal break;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a subretinal haemorrhage involving the centre of the fovea, or, if the size of the haemorrhage is &ge;50%, of the total lesion area;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; performed or planned intraocular surgery within the previous or next 28&nbsp;days.</p><p>&nbsp;</p><p><u>Retinal pigment epithelial tear</u></p><p>&nbsp;</p><p>Risk factors associated with the development of a retinal pigment epithelial tear after anti-VEGF therapy for wet AMD and potentially also other forms of CNV, include a large and/or high pigment epithelial retinal detachment. When initiating ranibizumab therapy, caution should be used in patients with these risk factors for retinal pigment epithelial tears.</p><p>&nbsp;</p><p><u>Rhegmatogenous retinal detachment or macular holes</u></p><p>&nbsp;</p><p>Treatment should be discontinued in subjects with rhegmatogenous retinal detachment or stage&nbsp;3 or 4 macular holes.</p><p>&nbsp;</p><p><u>Populations with limited data</u></p><p>&nbsp;</p><p>There is only limited experience in the treatment of subjects with DME due to type I diabetes. Lucentis has not been studied in patients who have previously received intravitreal injections, in patients with active systemic infections, proliferative diabetic retinopathy, or in patients with concurrent eye conditions such as retinal detachment or macular hole. There is also no experience of treatment with Lucentis in diabetic patients with an HbA1c over 12% and uncontrolled hypertension. This lack of information should be considered by the physician when treating such patients.</p><p>&nbsp;</p><p>There are insufficient data to conclude on the effect of Lucentis in patients with RVO presenting irreversible ischaemic visual function loss.</p><p>&nbsp;</p><p>In patients with PM, there are limited data on the effect of Lucentis in patients who have previously undergone unsuccessful verteporfin photodynamic therapy (vPDT) treatment. Also, while a consistent effect was observed in subjects with subfoveal and juxtafoveal lesions, there are insufficient data to conclude on the effect of Lucentis in PM subjects with extrafoveal lesions.</p><p>&nbsp;</p><p><u>Systemic effects following intravitreal use</u></p><p>&nbsp;</p><p>Systemic adverse events including non-ocular haemorrhages and arterial thromboembolic events have been reported following intravitreal injection of VEGF inhibitors.</p><p>&nbsp;</p><p>There are limited data on safety in the treatment of DME, macular oedema due to RVO and CNV secondary to PM patients with prior history of stroke or transient ischaemic attacks. Caution should be exercised when treating such patients (see section&nbsp;4.8)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <ul><li><p>No formal interaction studies have been performed.</p><p>&nbsp;</p><p>For the adjunctive use of verteporfin photodynamic therapy (PDT) and Lucentis in wet AMD and PM, see section&nbsp;5.1.</p><p>&nbsp;</p><p>For the adjunctive use of laser photocoagulation and Lucentis in DME and BRVO, see sections&nbsp;4.2 and 5.1.</p><p>&nbsp;</p><p>In clinical studies for the treatment of visual impairment due to DME, the outcome with regard to visual acuity or central retinal subfield thickness (CSFT) in patients treated with Lucentis was not affected by concomitant treatment with thiazolidinediones.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>No interaction studies have been performed.</p></li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential/contraception in females</u></p><p>Women of childbearing potential should use effective contraception during treatment.</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>For ranibizumab no clinical data on exposed pregnancies are available. Studies in cynomolgus monkeys do not indicate direct or indirect harmful effects with respect to pregnancy or embryonal/foetal development (see section&nbsp;5.3). The systemic exposure to ranibizumab is low after ocular administration, but due to its mechanism of action, ranibizumab must be regarded as potentially teratogenic and embryo-/foetotoxic. Therefore, ranibizumab should not be used during pregnancy unless the expected benefit outweighs the potential risk to the foetus. For women who wish to become pregnant and have been treated with ranibizumab, it is recommended to wait at least 3&nbsp;months after the last dose of ranibizumab before conceiving a child.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>Based on very limited data, ranibizumab may be excreted in human milk at low levels. The effect of ranibizumab on a breast-fed newborn/infant is unknown. As a precautionary measure, Breast-feeding is not recommended during the use of Lucentis.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>There are no data available on fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The treatment procedure may induce temporary visual disturbances, which may affect the ability to drive or use machines (see section&nbsp;4.8). Patients who experience these signs must not drive or use machines until these temporary visual disturbances subside.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>&nbsp;</p><p>The majority of adverse reactions reported following administration of Lucentis are related to the intravitreal injection procedure.</p><p>&nbsp;</p><p>The most frequently reported ocular adverse reactions following injection of Lucentis are: eye pain, ocular hyperaemia, increased intraocular pressure, vitritis, vitreous detachment, retinal haemorrhage, visual disturbance, vitreous floaters, conjunctival haemorrhage, eye irritation, foreign body sensation in eyes, increased lacrimation, blepharitis, dry eye and eye pruritus.</p><p>&nbsp;</p><p>The most frequently reported non-ocular adverse reactions are headache, nasopharyngitis and arthralgia.</p><p>&nbsp;</p><p>Less frequently reported, but more serious, adverse reactions include endophthalmitis, blindness, retinal detachment, retinal tear and iatrogenic traumatic cataract (see section&nbsp;4.4).</p><p>&nbsp;</p><p>The adverse reactions experienced following administration of Lucentis in clinical trials are summarised in the table below.</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions<sup>#</sup></u></p><p>&nbsp;</p><p>The adverse reactions are listed by system organ class and frequency using the following convention: very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100), rare (&ge;1/10,000 to &lt;1/1,000), very rare (&lt;1/10,000), not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Very common</em></p></td><td style="vertical-align:top"><p>Nasopharyngitis</p></td></tr><tr><td style="vertical-align:top"><p><em>Common</em></p></td><td style="vertical-align:top"><p>Urinary tract infection*</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td></tr><tr><td style="vertical-align:top"><p><em>Common</em></p></td><td style="vertical-align:top"><p>Anaemia</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Common</em></p></td><td style="vertical-align:top"><p>Hypersensitivity</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Common</em></p></td><td style="vertical-align:top"><p>Anxiety</p></td></tr><tr><td style="vertical-align:top"><p><em>&nbsp;</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Very common</em></p></td><td style="vertical-align:top"><p>Headache</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Very common</em></p></td><td style="vertical-align:top"><p>Vitritis, vitreous detachment, retinal haemorrhage, visual disturbance, eye pain, vitreous floaters, conjunctival haemorrhage, eye irritation, foreign body sensation in eyes, lacrimation increased, blepharitis, dry eye, ocular hyperaemia, eye pruritus.</p></td></tr><tr><td style="vertical-align:top"><p><em>Common</em></p></td><td style="vertical-align:top"><p>Retinal degeneration, retinal disorder, retinal detachment, retinal tear, detachment of the retinal pigment epithelium, retinal pigment epithelium tear, visual acuity reduced, vitreous haemorrhage, vitreous disorder, uveitis, iritis, iridocyclitis, cataract, cataract subcapsular, posterior capsule opacification, punctuate keratitis, corneal abrasion, anterior chamber flare, vision blurred, injection site haemorrhage, eye haemorrhage, conjunctivitis, conjunctivitis allergic, eye discharge, photopsia, photophobia, ocular discomfort, eyelid oedema, eyelid pain, conjunctival hyperaemia.</p></td></tr><tr><td style="vertical-align:top"><p><em>Uncommon</em></p></td><td style="vertical-align:top"><p>Blindness, endophthalmitis, hypopyon, hyphaema, keratopathy, iris adhesion, corneal deposits, corneal oedema, corneal striae, injection site pain, injection site irritation, abnormal sensation in eye, eyelid irritation.</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td></tr><tr><td style="vertical-align:top"><p><em>Common</em></p></td><td style="vertical-align:top"><p>Cough</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Common</em></p></td><td style="vertical-align:top"><p>Nausea</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td></tr><tr><td style="vertical-align:top"><p><em>Common</em></p></td><td style="vertical-align:top"><p>Allergic reactions (rash, urticaria, pruritus, erythema)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td></tr><tr><td style="vertical-align:top"><p><em>Very common</em></p></td><td style="vertical-align:top"><p>Arthralgia</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Very common</em></p></td><td style="vertical-align:top"><p>Intraocular pressure increased</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><sup>#</sup> Adverse reactions were defined as adverse events (in at least 0.5&nbsp;percentage points of patients) which occurred at a higher rate (at least 2&nbsp;percentage points) in patients receiving treatment with Lucentis 0.5&nbsp;mg than in those receiving control treatment (sham or verteporfin PDT).</p><p>* observed only in DME population</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Product-class-related adverse reactions</u></p><p>&nbsp;</p><p>In the wet AMD phase III studies, the overall frequency of non-ocular haemorrhages, an adverse event potentially related to systemic VEGF (vascular endothelial growth factor) inhibition, was slightly increased in ranibizumab-treated patients. However, there was no consistent pattern among the different haemorrhages. There is a theoretical risk of arterial thromboembolic events, including stroke and myocardial infarction, following intravitreal use of VEGF inhibitors. A low incidence rate of arterial thromboembolic events was observed in the Lucentis clinical trials in patients with AMD, CNV, DME and RVO and there were no major differences between the groups treated with ranibizumab compared to control.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>&nbsp;</p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions.</p><p>To report any side effect(s):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Saudi Arabia</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Saudi Food and Drug Authority National Pharmacovigilance Center (NPC):</p><p>&nbsp;</p><p>o Fax: +966112057662</p><p>o SFDA call center: 19999</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: https://ade.sfda.gov.sa</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patient Safety Department Novartis Consulting AG - Saudi Arabia:</p><p>&nbsp;</p><p>o Toll Free Number: 8001240078</p><p>o Phone: +966112658100</p><p>o Fax: +966112658107</p><p>o Email: adverse.events@novartis.com</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp; Other GCC States:</p><p>-&nbsp; Please contact the relevant competent authority</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cases of accidental overdose have been reported from the clinical studies in wet AMD and post-marketing data. Adverse reactions associated with these reported cases were intraocular pressure increased, transient blindness, reduced visual acuity, corneal oedema, corneal pain, and eye pain. If an overdose occurs, intraocular pressure should be monitored and treated, if deemed necessary by the attending physician.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Ophthalmologicals, antineovascularisation agents, ATC code: S01LA04</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>Ranibizumab is a humanised recombinant monoclonal antibody fragment targeted against human vascular endothelial growth factor A (VEGF-A). It binds with high affinity to the VEGF-A isoforms (e.g. VEGF<sub>110</sub>, VEGF<sub>121</sub> and VEGF<sub>165</sub>), thereby preventing binding of VEGF-A to its receptors VEGFR-1 and VEGFR-2. Binding of VEGF-A to its receptors leads to endothelial cell proliferation and neovascularisation, as well as vascular leakage, all of which are thought to contribute to the progression of the neovascular form of age-related macular degeneration, pathologic myopia and CNV or to visual impairment caused by either diabetic macular oedema or macular oedema secondary to RVO.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>&nbsp;</p><p><em><u>Treatment of wet AMD</u></em></p><p>In wet AMD, the clinical safety and efficacy of Lucentis have been assessed in three randomised, double-masked, sham- or active-controlled studies of 24&nbsp;months duration in patients with neovascular AMD. A total of 1,323&nbsp;patients (879&nbsp;active and 444&nbsp;control) were enrolled in these studies.</p><p>&nbsp;</p><p>In study FVF2598g (MARINA), 716&nbsp;patients with minimally classic or occult with no classic lesions were randomised in a 1:1:1&nbsp;ratio to receive monthly injections of Lucentis 0.3&nbsp;mg, Lucentis 0.5&nbsp;mg or sham.</p><p>&nbsp;</p><p>In study FVF2587g (ANCHOR), 423&nbsp;patients with predominantly classic CNV lesions were randomised in a 1:1:1&nbsp;ratio to receive Lucentis 0.3&nbsp;mg monthly, Lucentis 0.5&nbsp;mg monthly or verteporfin PDT (at baseline and every 3&nbsp;months thereafter if fluorescein angiography showed persistence or recurrence of vascular leakage).</p><p>&nbsp;</p><p>Key outcome measures are summarised in Table&nbsp;1 and Figure&nbsp;1.</p><p><strong>Table&nbsp;1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Outcomes at Month&nbsp;12 and Month&nbsp;24 in study FVF2598g (MARINA) and FVF2587g (ANCHOR)</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>FVF2598g (MARINA)</p></td><td colspan="2" style="vertical-align:top"><p>FVF2587g (ANCHOR)</p></td></tr><tr><td style="vertical-align:top"><p>Outcome measure</p></td><td style="vertical-align:top"><p>Month</p></td><td style="vertical-align:top"><p>Sham</p><p>(n=238)</p></td><td style="vertical-align:top"><p>Lucentis 0.5&nbsp;mg</p><p>(n=240)</p></td><td style="vertical-align:top"><p>Verteporfin PDT (n=143)</p></td><td style="vertical-align:top"><p>Lucentis 0.5&nbsp;mg (n=140)</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Loss of &lt;15&nbsp;letters in visual acuity (%)<sup>a</sup></p><p>(maintenance of vision, primary endpoint)</p></td><td style="vertical-align:top"><p>Month&nbsp;12</p></td><td style="vertical-align:top"><p>62%</p></td><td style="vertical-align:top"><p>95%</p></td><td style="vertical-align:top"><p>64%</p></td><td style="vertical-align:top"><p>96%</p></td></tr><tr><td style="vertical-align:top"><p>Month&nbsp;24</p></td><td style="vertical-align:top"><p>53%</p></td><td style="vertical-align:top"><p>90%</p></td><td style="vertical-align:top"><p>66%</p></td><td style="vertical-align:top"><p>90%</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Gain of &ge;15&nbsp;letters in visual acuity (%)<sup>a</sup></p></td><td style="vertical-align:top"><p>Month&nbsp;12</p></td><td style="vertical-align:top"><p>5%</p></td><td style="vertical-align:top"><p>34%</p></td><td style="vertical-align:top"><p>6%</p></td><td style="vertical-align:top"><p>40%</p></td></tr><tr><td style="vertical-align:top"><p>Month&nbsp;24</p></td><td style="vertical-align:top"><p>4%</p></td><td style="vertical-align:top"><p>33%</p></td><td style="vertical-align:top"><p>6%</p></td><td style="vertical-align:top"><p>41%</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Mean change in visual acuity (letters) (SD)<sup>a</sup></p></td><td style="vertical-align:top"><p>Month&nbsp;12</p></td><td style="vertical-align:top"><p>‑10.5 (16.6)</p></td><td style="vertical-align:top"><p>+7.2 (14.4)</p></td><td style="vertical-align:top"><p>‑9.5 (16.4)</p></td><td style="vertical-align:top"><p>+11.3 (14.6)</p></td></tr><tr><td style="vertical-align:top"><p>Month&nbsp;24</p></td><td style="vertical-align:top"><p>‑14.9 (18.7)</p></td><td style="vertical-align:top"><p>+6.6 (16.5)</p></td><td style="vertical-align:top"><p>‑9.8 (17.6)</p></td><td style="vertical-align:top"><p>+10.7 (16.5)</p></td></tr><tr><td style="vertical-align:top"><p><sup>a </sup>p&lt;0.01</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Figure&nbsp;1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mean change in visual acuity from baseline to Month&nbsp;24 in study FVF2598g (MARINA) and study FVF2587g (ANCHOR)</strong></p><p><strong>(figure cannot be uploaded here)</strong></p><p>&nbsp;</p><p>Results from both trials indicated that continued ranibizumab treatment may also be of benefit in patients who lost &ge;15&nbsp;letters of best-corrected visual acuity (BCVA) in the first year of treatment.</p><p>&nbsp;</p><p>Statistically significant patient-reported visual functioning benefits were observed in both MARINA and ANCHOR with ranibizumab treatment over the control group as measured by the NEI VFQ-25.</p><p>&nbsp;</p><p>In study FVF3192g (PIER), 184&nbsp;patients with all forms of neovascular AMD were randomised in a 1:1:1&nbsp;ratio to receive Lucentis 0.3&nbsp;mg, Lucentis 0.5&nbsp;mg or sham injections once a month for 3&nbsp;consecutive doses, followed by a dose administered once every 3&nbsp;months. From Month&nbsp;14 of the study, sham-treated patients were allowed to receive ranibizumab and from Month&nbsp;19, more frequent treatments were possible. Patients treated with Lucentis in PIER received a mean of 10&nbsp;total treatments.</p><p>&nbsp;</p><p>After an initial increase in visual acuity (following monthly dosing), on average, patients&rsquo; visual acuity declined with quarterly dosing, returning to baseline at Month&nbsp;12 and this effect was maintained in most ranibizumab-treated patients (82%) at Month&nbsp;24. Limited data from sham subjects who later received ranibizumab suggested that early initiation of treatment may be associated with better preservation of visual acuity.</p><p>&nbsp;</p><p>Data from two studies (MONT BLANC, BPD952A2308 and DENALI, BPD952A2309) conducted post approval confirmed the efficacy of Lucentis but did not demonstrate additional effect of the combined administration of verteporfin (Visudyne PDT) and Lucentis compared to Lucentis monotherapy.</p><p>&nbsp;</p><p><em><u>Treatment of visual impairment due to CNV secondary to PM</u></em></p><p>The clinical safety and efficacy of Lucentis in patients with visual impairment due to CNV in PM have been assessed based on the 12‑month data of the double-masked, controlled pivotal study F2301 (RADIANCE). In this study 277&nbsp;patients were randomised in a 2:2:1 ratio to the following arms:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Group I (ranibizumab 0.5&nbsp;mg, dosing regimen driven by &ldquo;stability&rdquo; criteria defined as no change in BCVA compared to two preceding monthly evaluations).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Group II (ranibizumab 0.5&nbsp;mg, dosing regimen driven by &ldquo;disease activity&rdquo; criteria defined as vision impairment attributable to intra- or subretinal fluid or active leakage due to the CNV lesion as assessed by optical coherence tomography and/or fluorescence angiography).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Group III (vPDT - patients were allowed to receive ranibizumab treatment as of Month&nbsp;3).</p><p>In Group II, which is the recommended posology (see section&nbsp;4.2), 50.9% of patients required 1 or 2&nbsp;injections, 34.5% required 3 to 5&nbsp;injections and 14.7% required 6 to 12&nbsp;injections over the 12‑month study period. 62.9% of Group II patients did not require injections in the second 6&nbsp;months of the study.</p><p>&nbsp;</p><p>The key outcomes from RADIANCE are summarised in Table&nbsp;2 and Figure&nbsp;2.</p><p>&nbsp;</p><p><strong>Table&nbsp;2 Outcomes at Month&nbsp;3 and 12 (RADIANCE)</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Group I</strong></p><p><strong>Ranibizumab</strong></p><p><strong>0.5&nbsp;mg</strong></p><p><strong>&ldquo;vision stability&rdquo;</strong></p><p><strong>(n=105)</strong></p></td><td style="vertical-align:top"><p><strong>Group II</strong></p><p><strong>Ranibizumab</strong></p><p><strong>0.5&nbsp;mg</strong></p><p><strong>&ldquo;disease activity&rdquo;</strong></p><p><strong>(n=116)</strong></p></td><td style="vertical-align:top"><p><strong>Group III</strong></p><p><strong>vPDT</strong><strong><sup>b</sup></strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>(n=55)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Month&nbsp;3</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Mean average BCVA change from Month&nbsp;1 to Month&nbsp;3 compared to baseline<sup>a</sup> (letters)</p></td><td style="vertical-align:top"><p>+10.5</p></td><td style="vertical-align:top"><p>+10.6</p></td><td style="vertical-align:top"><p>+2.2</p></td></tr><tr><td style="vertical-align:top"><p>Proportion of patients who gained:</p><p>&ge;15&nbsp;letters, or reached &ge;84&nbsp;letters in BCVA</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>38.1%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>43.1%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>14.5%</p></td></tr><tr><td style="vertical-align:top"><p><strong>Month&nbsp;12</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Number of injections up to Month&nbsp;12:</p><p>Mean</p><p>Median</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>4.6</p><p>4.0</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>3.5</p><p>2.5</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>N/A</p><p>N/A</p></td></tr><tr><td style="vertical-align:top"><p>Mean average BCVA change from Month&nbsp;1 to Month&nbsp;12 compared to baseline (letters)</p></td><td style="vertical-align:top"><p>+12.8</p></td><td style="vertical-align:top"><p>+12.5</p></td><td style="vertical-align:top"><p>N/A</p></td></tr><tr><td style="vertical-align:top"><p>Proportion of patients who gained:</p><p>&ge;15&nbsp;letters, or reached &ge;84&nbsp;letters in BCVA</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>53.3%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>51.7%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>N/A</p></td></tr></tbody></table><p><sup>a</sup> p&lt;0.00001 comparison with vPDT control</p><p><sup>b</sup> Comparative control up to Month&nbsp;3. Patients randomised to vPDT were allowed to receive ranibizumab treatment as of Month&nbsp;3 (in Group III, 38&nbsp;patients received ranibizumab as of Month&nbsp;3)</p><p><strong>Figure&nbsp;2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mean change from baseline BCVA over time to Month&nbsp;12 (RADIANCE)</strong></p><p><strong>(figure cannot be uploaded here)</strong></p><p>&nbsp;</p><p>The improvement of vision was accompanied by a reduction in central retinal thickness.</p><p>&nbsp;</p><p>Patient-reported benefits were observed with ranibizumab treatment arms over vPDT (p-value &lt;0.05) in terms of improvement in the composite score and several subscales (general vision, near activities, mental health and dependency) of the NEI VFQ-25.</p><p>&nbsp;</p><p><em><u>Treatment of visual impairment due to CNV (other than secondary to PM and wet AMD)</u></em></p><p>The clinical safety and efficacy of Lucentis in patients with visual impairment due to CNV have been assessed based on the 12-month data of the double-masked, sham-controlled pivotal study G2301 (MINERVA). In this study 178&nbsp;adult patients were randomised in a 2:1 ratio to receive:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ranibizumab 0.5&nbsp;mg at baseline, followed by an individualised dosing regimen driven by disease activity as assessed by visual acuity and/or anatomical parameters (e.g. VA impairment, intra/sub-retinal fluid, haemorrhage or leakage);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sham injection at baseline, followed by an individualised treatment regimen driven by disease activity.</p><p>At Month&nbsp;2, all patients received open-label treatment with ranibizumab as needed.</p><p>&nbsp;</p><p>Key outcome measures from MINERVA are summarised in Table&nbsp;3 and Figure&nbsp;3. An improvement of vision was observed and was accompanied by a reduction in central subfield thickness over the 12‑month period.</p><p>&nbsp;</p><p>The mean number of injections given over 12&nbsp;months was 5.8 in the ranibizumab arm versus 5.4 in those patients in the sham arm who were eligible to receive ranibizumab from Month&nbsp;2 onwards. In the sham arm 7 out of 59&nbsp;patients did not receive any treatment with ranibizumab in the study eye during the 12-month period.</p><p>&nbsp;</p><p><strong>Table&nbsp;3 Outcomes at Month&nbsp;2 (MINERVA)</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Ranibizumab 0.5&nbsp;mg (n=119)</strong></p></td><td style="vertical-align:top"><p><strong>Sham (n=59)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Mean BCVA change from baseline to Month&nbsp;2&nbsp;<sup>a </sup></p></td><td style="vertical-align:top"><p>9.5&nbsp;letters</p></td><td style="vertical-align:top"><p>‑0.4&nbsp;letters</p></td></tr><tr><td style="vertical-align:top"><p>Patients gaining &ge;15&nbsp;letters from baseline or reaching 84&nbsp;letters at Month&nbsp;2</p></td><td style="vertical-align:top"><p>31.4%</p></td><td style="vertical-align:top"><p>12.3%</p></td></tr><tr><td style="vertical-align:top"><p>Patients not losing &gt;15&nbsp;letters from baseline at Month&nbsp;2</p></td><td style="vertical-align:top"><p>99.2%</p></td><td style="vertical-align:top"><p>94.7%</p></td></tr><tr><td style="vertical-align:top"><p>Reduction in CSFT<sup>b</sup> from baseline to Month&nbsp;2<sup> a</sup></p></td><td style="vertical-align:top"><p>77&nbsp;&micro;m</p></td><td style="vertical-align:top"><p>‑9.8&nbsp;&micro;m</p></td></tr></tbody></table><p><sup>a</sup> One-sided p&lt;0.001 comparison with sham control</p><p><sup>b</sup> CSFT - central retinal subfield thickness</p><p>&nbsp;</p><p><strong>Figure&nbsp;3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mean change from baseline BCVA over time to Month&nbsp;12 (MINERVA)</strong></p><p><strong>(figure cannot be uploaded here)</strong></p><p>&nbsp;</p><p>When comparing ranibizumab versus sham control at Month&nbsp;2, a consistent treatment effect both overall and across baseline aetiology subgroups was observed:</p><p>&nbsp;</p><p><strong>Table&nbsp;4 Treatment effect overall and across baseline aetiology subgroups</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Overall and per baseline aetiology</strong></p></td><td style="vertical-align:top"><p><strong>Treatment effect over sham [letters]</strong></p></td><td style="vertical-align:top"><p><strong>Patient numbers [n] (treatment +sham)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Overall</p></td><td style="vertical-align:top"><p>9.9</p></td><td style="vertical-align:top"><p>178</p></td></tr><tr><td style="vertical-align:top"><p>Angioid streaks</p></td><td style="vertical-align:top"><p>14.6</p></td><td style="vertical-align:top"><p>27</p></td></tr><tr><td style="vertical-align:top"><p>Post-inflammatory retinochoroidopathy</p></td><td style="vertical-align:top"><p>6.5</p></td><td style="vertical-align:top"><p>28</p></td></tr><tr><td style="vertical-align:top"><p>Central serous chorioretinopathy</p></td><td style="vertical-align:top"><p>5.0</p></td><td style="vertical-align:top"><p>23</p></td></tr><tr><td style="vertical-align:top"><p>Idiopathic chorioretinopathy</p></td><td style="vertical-align:top"><p>11.4</p></td><td style="vertical-align:top"><p>63</p></td></tr><tr><td style="vertical-align:top"><p>Miscellaneous aetiologies<sup>a</sup></p></td><td style="vertical-align:top"><p>10.6</p></td><td style="vertical-align:top"><p>37</p></td></tr></tbody></table><p><sup>a</sup> encompasses different aetiologies of low frequency of occurrence not included in the other subgroups</p><p>&nbsp;</p><p>In the pivotal study G2301 (MINERVA), five adolescent patients aged 12 to 17&nbsp;years with visual impairment secondary to CNV received open-label treatment with ranibizumab 0.5&nbsp;mg at baseline followed by an individualised treatment regimen as for the adult population. BCVA improved from baseline to Month&nbsp;12 in all five patients, ranging from 5 to 38&nbsp;letters (mean of 16.6&nbsp;letters). The improvement of vision was accompanied by a stabilisation or reduction in central subfield thickness over the 12-month period. The mean number of ranibizumab injections given in the study eye over 12&nbsp;months was 3 (ranged from 2 to 5). Overall, ranibizumab treatment was well tolerated.</p><p>&nbsp;</p><p><em><u>Treatment of visual impairment due to DME</u></em></p><p>The efficacy and safety of Lucentis have been assessed in three randomised, controlled studies of at least 12&nbsp;months duration. A total of 868&nbsp;patients (708&nbsp;active and 160&nbsp;control) were enrolled in these studies.</p><p>&nbsp;</p><p>In the phase II study D2201 (RESOLVE), 151&nbsp;patients were treated with ranibizumab (6&nbsp;mg/ml, n=51, 10&nbsp;mg/ml, n=51) or sham (n=49) by monthly intravitreal injections. The mean average change in BCVA from Month&nbsp;1 to Month&nbsp;12 compared to baseline was +7.8 (&plusmn;7.72) letters in the pooled ranibizumab-treated patients (n=102), compared to ‑0.1 (&plusmn;9.77) letters for sham-treated patients; and the mean change in BCVA at Month&nbsp;12 from baseline was 10.3 (&plusmn;9.1) letters compared to ‑1.4&nbsp;(&plusmn;14.2) letters, respectively (p&lt;0.0001 for the treatment difference).</p><p>&nbsp;</p><p>In the phase&nbsp;III study D2301 (RESTORE), 345&nbsp;patients were randomised in a 1:1:1&nbsp;ratio to receive ranibizumab 0.5&nbsp;mg monotherapy and sham laser photocoagulation, combined ranibizumab 0.5&nbsp;mg and laser photocoagulation or sham injection and laser photocoagulation. 240&nbsp;patients, who had previously completed the 12‑month RESTORE study, were enrolled in the open-label, multicentre 24‑month extension (RESTORE Extension) study. Patients were treated with ranibizumab 0.5&nbsp;mg <em>pro re nata</em> (PRN) in the same eye as the core study (D2301 RESTORE).</p><p>Key outcome measures are summarised in Table&nbsp;5 (RESTORE and Extension) and Figure&nbsp;4 (RESTORE).</p><p>&nbsp;</p><p><strong>Figure&nbsp;4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Mean change in visual acuity from baseline over time in study D2301 (RESTORE)</strong></p><p><strong>(figure cannot be uploaded here)</strong></p><p>&nbsp;</p><p>BL=baseline; SE=standard error of mean</p><p>* Difference in least square means, p&lt;0.0001/0.0004 based on two-sided stratified Cochran-Mantel-Haenszel test</p><p>&nbsp;</p><p>The effect at 12&nbsp;months was consistent in most subgroups. However, subjects with a baseline BCVA &gt;73&nbsp;letters and macular oedema with central retinal thickness &lt;300&nbsp;&micro;m did not appear to benefit from treatment with ranibizumab compared to laser photocoagulation.</p><p>&nbsp;</p><p><strong>Table&nbsp;5 Outcomes at Month&nbsp;12 in study D2301 (RESTORE) and at Month&nbsp;36 in study D2301-E1 (RESTORE Extension)</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Outcome measures at Month&nbsp;12 compared to baseline in study D2301 (RESTORE)</p></td><td style="vertical-align:top"><p>Ranibizumab</p><p>0.5&nbsp;mg</p><p>n=115</p></td><td style="vertical-align:top"><p>Ranibizumab</p><p>0.5&nbsp;mg + Laser n=118</p></td><td style="vertical-align:top"><p>Laser</p><p>&nbsp;</p><p>n=110</p></td></tr><tr><td style="vertical-align:top"><p>Mean average change in BCVA from Month&nbsp;1 to Month&nbsp;12<sup>a</sup> (&plusmn;SD)</p></td><td style="vertical-align:top"><p>6.1 (6.4)<sup>a</sup></p></td><td style="vertical-align:top"><p>5.9 (7.9)<sup>a</sup></p></td><td style="vertical-align:top"><p>0.8 (8.6)</p></td></tr><tr><td style="vertical-align:top"><p>Mean change in BCVA at Month&nbsp;12 (&plusmn;SD)</p></td><td style="vertical-align:top"><p>6.8 (8.3)<sup>a</sup></p></td><td style="vertical-align:top"><p>6.4 (11.8)<sup>a</sup></p></td><td style="vertical-align:top"><p>0.9 (11.4)</p></td></tr><tr><td style="vertical-align:top"><p>Gain of &ge;15&nbsp;letters or BCVA &ge;84&nbsp;letters at Month 12 (%)</p></td><td style="vertical-align:top"><p>22.6</p></td><td style="vertical-align:top"><p>22.9</p></td><td style="vertical-align:top"><p>8.2</p></td></tr><tr><td style="vertical-align:top"><p>Mean number of injections (Months 0‑11)</p></td><td style="vertical-align:top"><p>7.0</p></td><td style="vertical-align:top"><p>6.8</p></td><td style="vertical-align:top"><p>7.3 (sham)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Outcome measure at Month&nbsp;36 compared to D2301 (RESTORE) baseline in study D2301-E1 (RESTORE Extension)</p></td><td style="vertical-align:top"><p>Prior ranibizumab</p><p>0.5&nbsp;mg</p><p>n=83</p></td><td style="vertical-align:top"><p>Prior ranibizumab</p><p>0.5&nbsp;mg + laser</p><p>n=83</p></td><td style="vertical-align:top"><p>Prior laser</p><p>&nbsp;</p><p>n=74</p></td></tr><tr><td style="vertical-align:top"><p>Mean change in BCVA at Month&nbsp;24 (SD)</p></td><td><p>7.9 (9.0)</p></td><td><p>6.7 (7.9)</p></td><td><p>5.4 (9.0)</p></td></tr><tr><td style="vertical-align:top"><p>Mean change in BCVA at Month&nbsp;36 (SD)</p></td><td><p>8.0 (10.1)</p></td><td><p>6.7 (9.6)</p></td><td><p>6.0 (9.4)</p></td></tr><tr><td style="vertical-align:top"><p>Gain of &ge;15&nbsp;letters or BCVA &ge;84&nbsp;letters at Month&nbsp;36 (%)</p></td><td><p>27.7</p></td><td><p>30.1</p></td><td><p>21.6</p></td></tr><tr><td style="vertical-align:top"><p>Mean number of injections (Months&nbsp;12‑35)*</p></td><td><p>6.8</p></td><td><p>6.0</p></td><td><p>6.5</p></td></tr></tbody></table><p><sup>a</sup>p&lt;0.0001 for comparisons of ranibizumab arms vs. laser arm.</p><p>n in D2301-E1 (RESTORE Extension) is the number of patients with a value at both D2301 (RESTORE) baseline (Month&nbsp;0) and at the Month&nbsp;36 visit.</p><p>* The proportion of patients who did not require any ranibizumab treatment during the extension phase was 19%, 25% and 20% in the prior ranibizumab, prior ranibizumab + laser and prior laser groups, respectively.</p><p>&nbsp;</p><p>Statistically significant patient-reported benefits for most vision-related functions were observed with ranibizumab (with or without laser) treatment over the control group as measured by the NEI VFQ-25.<strong> </strong>For other subscales of this questionnaire no treatment differences could be established.</p><p>&nbsp;</p><p>The long‑term safety profile of ranibizumab observed in the 24‑month extension study is consistent with the known Lucentis safety profile.</p><p>&nbsp;</p><p>In the phase IIIb study D2304 (RETAIN), 372&nbsp;patients were randomised in 1:1:1&nbsp;ratio to receive:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ranibizumab 0.5&nbsp;mg with concomitant laser photocoagulation on a treat-and-extend (TE) regimen,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ranibizumab 0.5&nbsp;mg monotherapy on a TE regimen,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ranibizumab 0.5&nbsp;mg monotherapy on a PRN regimen.</p><p>&nbsp;</p><p>In all groups, ranibizumab was administered monthly until BCVA was stable for at least three consecutive monthly assessments. On TE, ranibizumab was administered at treatment intervals of 2‑3&nbsp;months. In all groups, monthly treatment was re-initiated upon a decrease in BCVA due to DME progression and continued until stable BCVA was reached again.</p><p>&nbsp;</p><p>The number of scheduled treatment visits after the initial 3&nbsp;injections, was 13 and 20 for the TE and PRN regimens, respectively. With both TE regimens, more than 70% of patients maintained their BCVA with an average visit frequency of &ge;2&nbsp;months.</p><p>&nbsp;</p><p>The key outcome measures are summarised in Table&nbsp;6.</p><p>&nbsp;</p><p><strong>Table&nbsp;6 </strong><strong>Outcomes in study D2304 (RETAIN)</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td style="vertical-align:top"><p>Outcome measure compared to baseline</p></td><td style="vertical-align:top"><p>TE ranibizumab</p><p>0.5&nbsp;mg + laser</p><p>n=117</p></td><td style="vertical-align:top"><p>TE ranibizumab</p><p>0.5&nbsp;mg alone</p><p>n=125</p></td><td style="vertical-align:top"><p>PRN ranibizumab</p><p>0.5&nbsp;mg</p><p>n=117</p></td></tr><tr><td style="vertical-align:top"><p>Mean average change in BCVA from Month&nbsp;1 to Month&nbsp;12 (SD)</p></td><td><p>5.9 (5.5)<sup> a</sup></p></td><td><p>6.1 (5.7)<sup> a</sup></p></td><td><p>6.2 (6.0)</p></td></tr><tr><td style="vertical-align:top"><p>Mean average change in BCVA from Month&nbsp;1 to Month&nbsp;24 (SD)</p></td><td><p>6.8 (6.0)</p></td><td><p>6.6 (7.1)</p></td><td><p>7.0 (6.4)</p></td></tr><tr><td style="vertical-align:top"><p>Mean change in BCVA at Month&nbsp;24 (SD)</p></td><td><p>8.3 (8.1)</p></td><td><p>6.5 (10.9)</p></td><td><p>8.1 (8.5)</p></td></tr><tr><td style="vertical-align:top"><p>Gain of &ge;15&nbsp;letters or BCVA &ge;84&nbsp;letters at Month&nbsp;24(%)</p></td><td><p>25.6</p></td><td><p>28.0</p></td><td><p>30.8</p></td></tr><tr><td style="vertical-align:top"><p>Mean number of injections (months&nbsp;0‑23)</p></td><td><p>12.4</p></td><td><p>12.8</p></td><td><p>10.7</p></td></tr></tbody></table><p><sup>a</sup>p&lt;0.0001 for assessment of non-inferiority to PRN</p><p>&nbsp;</p><p>In DME studies, the improvement in BCVA was accompanied by a reduction over time in mean CSFT in all the treatment groups.</p><p>&nbsp;</p><p><em><u>Treatment of visual impairment due to macular oedema secondary to RVO</u></em></p><p>The clinical safety and efficacy of Lucentis in patients with visual impairment due to macular oedema secondary to RVO have been assessed in the randomised, double-masked, controlled studies BRAVO and CRUISE that recruited subjects with BRVO (n=397) and CRVO (n=392), respectively. In both studies, subjects received either 0.3&nbsp;mg or 0.5&nbsp;mg ranibizumab or sham injections. After 6&nbsp;months, patients in the sham-control arms switched to 0.5&nbsp;mg ranibizumab</p><p>Key outcome measures from BRAVO and CRUISE are summarised in Table&nbsp;7 and Figures&nbsp;5 and 6.</p><p>&nbsp;</p><p><strong>Table&nbsp;7 Outcomes at Month&nbsp;6 and 12 (BRAVO and CRUISE)</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:101%"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>BRAVO</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>CRUISE</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Sham/Lucentis 0.5&nbsp;mg</strong></p><p><strong>(n=132)</strong></p></td><td style="vertical-align:top"><p><strong>Lucentis 0.5&nbsp;mg</strong></p><p><strong>(n=131)</strong></p></td><td style="vertical-align:top"><p><strong>Sham/Lucentis 0.5&nbsp;mg</strong></p><p><strong>(n=130)</strong></p></td><td style="vertical-align:top"><p><strong>Lucentis 0.5&nbsp;mg</strong></p><p><strong>(n=130)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Mean change in visual acuity at Month&nbsp;6<sup>a</sup> (letters) (SD) (primary endpoint)</p></td><td style="vertical-align:top"><p>7.3 (13.0)</p></td><td style="vertical-align:top"><p>18.3 (13.2)</p></td><td style="vertical-align:top"><p>0.8 (16.2)</p></td><td style="vertical-align:top"><p>14.9 (13.2)</p></td></tr><tr><td style="vertical-align:top"><p>Mean change in BCVA at Month&nbsp;12 (letters) (SD)</p></td><td style="vertical-align:top"><p>12.1 (14.4)</p></td><td style="vertical-align:top"><p>18.3 (14.6)</p></td><td style="vertical-align:top"><p>7.3 (15.9)</p></td><td style="vertical-align:top"><p>13.9 (14.2)</p></td></tr><tr><td style="vertical-align:top"><p>Gain of &ge;15&nbsp;letters in visual acuity at Month&nbsp;6<sup>a</sup> (%)</p></td><td style="vertical-align:top"><p>28.8</p></td><td style="vertical-align:top"><p>61.1</p></td><td style="vertical-align:top"><p>16.9</p></td><td style="vertical-align:top"><p>47.7</p></td></tr><tr><td style="vertical-align:top"><p>Gain of &ge;15&nbsp;letters in visual acuity at Month&nbsp;12 (%)</p></td><td style="vertical-align:top"><p>43.9</p></td><td style="vertical-align:top"><p>60.3</p></td><td style="vertical-align:top"><p>33.1</p></td><td style="vertical-align:top"><p>50.8</p></td></tr><tr><td style="vertical-align:top"><p>Proportion (%) receiving laser rescue over 12&nbsp;months</p></td><td style="vertical-align:top"><p>61.4</p></td><td style="vertical-align:top"><p>34.4</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>NA</p></td></tr></tbody></table><p><sup>a</sup>p&lt;0.0001for both studies</p><p>&nbsp;</p><p><strong>Figure&nbsp;5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mean change from baseline BCVA over time to Month&nbsp;6 and Month&nbsp;12 (BRAVO)</strong></p><p><strong>(figure cannot be uploaded here)</strong></p><p><strong>Figure&nbsp;6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mean change from baseline BCVA over time to Month&nbsp;6 and Month&nbsp;12 (CRUISE)</strong></p><p><strong>(figure cannot be uploaded here)</strong></p><p>&nbsp;</p><p>In both studies, the improvement of vision was accompanied by a continuous and significant reduction in the macular oedema as measured by central retinal thickness.</p><p>&nbsp;</p><p>In patients with CRVO (CRUISE and extension study HORIZON): Subjects treated with sham in the first 6&nbsp;months who subsequently received ranibizumab did not achieve comparable gains in VA by Month&nbsp;24 (~6&nbsp;letters) compared to subjects treated with ranibizumab from study start (~12&nbsp;letters).</p><p>&nbsp;</p><p>Statistically significant patient-reported benefits in subscales related to near and distance activity were observed with ranibizumab treatment over the control group as measured by the NEI VFQ-25.</p><p>&nbsp;</p><p>The long-term (24&nbsp;months) clinical safety and efficacy of Lucentis in patients with visual impairment due to macular oedema secondary to RVO were assessed in the BRIGHTER (BRVO) and CRYSTAL (CRVO) studies. In both studies, subjects received a 0.5&nbsp;mg ranibizumab PRN dosing regimen driven by individualised stabilisation criteria. BRIGHTER was a 3-arm randomised active-controlled study that compared 0.5&nbsp;mg ranibizumab given as monotherapy or in combination with adjunctive laser photocoagulation to laser photocoagulation alone. After 6&nbsp;months, subjects in the laser arm could receive 0.5&nbsp;mg ranibizumab. CRYSTAL was a single-arm study with 0.5&nbsp;mg ranibizumab monotherapy.</p><p>&nbsp;</p><p>Key outcome measures from BRIGHTER and CRYSTAL are shown in Table&nbsp;8.</p><p>&nbsp;</p><p><strong>Table&nbsp;8 Outcomes at Months&nbsp;6 and 24 (BRIGHTER and CRYSTAL)</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>BRIGHTER</strong></p></td><td style="vertical-align:top"><p><strong>CRYSTAL</strong></p></td></tr><tr><td style="vertical-align:top"><p><sup>&nbsp;</sup></p></td><td style="vertical-align:top"><p>Lucentis 0.5&nbsp;mg</p><p>N=180</p></td><td style="vertical-align:top"><p>Lucentis 0.5&nbsp;mg + Laser</p><p>N=178</p></td><td style="vertical-align:top"><p>Laser*</p><p>N=90</p></td><td style="vertical-align:top"><p>Lucentis 0.5&nbsp;mg</p><p>N=356</p></td></tr><tr><td style="vertical-align:top"><p>Mean change in BCVA at Month&nbsp;6<sup>a</sup> (letters) (SD)</p></td><td><p>+14.8</p><p>(10.7)</p></td><td><p>+14.8</p><p>(11.13)</p></td><td><p>+6.0</p><p>(14.27)</p></td><td><p>+12.0</p><p>(13.95)</p></td></tr><tr><td style="vertical-align:top"><p>Mean change in BCVA at Month&nbsp;24<sup>b</sup> (letters) (SD)</p></td><td><p>+15.5</p><p>(13.91)</p></td><td><p>+17.3</p><p>(12.61)</p></td><td><p>+11.6</p><p>(16.09)</p></td><td><p>+12.1</p><p>(18.60)</p></td></tr><tr><td style="vertical-align:top"><p>Gain of &ge;15&nbsp;letters in BCVA at Month&nbsp;24 (%)</p></td><td><p>52.8</p></td><td><p>59.6</p></td><td><p>43.3</p></td><td><p>49.2</p></td></tr><tr><td style="vertical-align:top"><p>Mean number of injections (SD) (Months&nbsp;0‑23)</p></td><td><p>11.4</p><p>(5.81)</p></td><td><p>11.3 (6.02)</p></td><td><p>NA</p></td><td><p>13.1 (6.39)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><sup>a</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; p&lt;0.0001for both comparisons in BRIGHTER at Month&nbsp;6: Lucentis 0.5&nbsp;mg vs Laser and Lucentis 0.5&nbsp;mg + Laser vs Laser.</p><p><sup>b</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; p&lt;0.0001for null hypothesis in CRYSTAL that the mean change at Month&nbsp;24 from baseline is zero.</p><p>*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Starting at Month&nbsp;6 ranibizumab 0.5&nbsp;mg treatment was allowed (24&nbsp;patients were treated with laser only).</p></td></tr></tbody></table><p>&nbsp;</p><p>In BRIGHTER, ranibizumab 0.5&nbsp;mg with adjunctive laser therapy demonstrated non-inferiority versus ranibizumab monotherapy from baseline to Month&nbsp;24 (95% CI -2.8, 1.4).</p><p>&nbsp;</p><p>In both studies, a rapid and statistically significant decrease from baseline in central retinal subfield thickness was observed at Month&nbsp;1. This <!--[if supportFields]><span lang=EN-GB
style='color:black'><span style='mso-element:field-begin'></span><span
style='mso-spacerun:yes'>  </span></span><![endif]--><!--[if supportFields]><span
lang=EN-GB style='color:black'><span style='mso-element:field-end'></span></span><![endif]-->effect was maintained up to Month&nbsp;24.</p><p>&nbsp;</p><p>The effect of ranibizumab treatment was similar irrespective of the presence of retinal ischaemia. In BRIGHTER, patients with ischaemia present (N=46) or absent (N=133) and treated with ranibizumab monotherapy had a mean change from baseline of +15.3 and +15.6&nbsp;letters, respectively, at Month&nbsp;24. In CRYSTAL, patients with ischaemia present (N=53) or absent (N=300) and treated with ranibizumab monotherapy had a mean change from baseline of +15.0 and +11.5&nbsp;letters, respectively.</p><p>&nbsp;</p><p>The effect in terms of visual improvement was observed in all patients treated with 0.5&nbsp;mg ranibizumab monotherapy regardless of their disease duration in both BRIGHTER and CRYSTAL. In patients with &lt;3&nbsp;months disease duration an increase in visual acuity of 13.3 and 10.0&nbsp;letters was seen at Month&nbsp;1; and 17.7 and 13.2&nbsp;letters at Month&nbsp;24 in BRIGHTER and CRYSTAL, respectively. The corresponding visual acuity gain in patients with &ge;12&nbsp;months disease duration was 8.6 and 8.4&nbsp;letters in the respective studies. Treatment initiation at the time of diagnosis should be considered.</p><p>&nbsp;</p><p>The long‑term safety profile of ranibizumab observed in the 24‑month studies is consistent with the known Lucentis safety profile.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>The safety and efficacy of ranibizumab have not yet been established in paediatric patients.</p><p>&nbsp;</p><p>The European Medicines Agency has waived the obligation to submit the results of studies with Lucentis in all subsets of the paediatric population in neovascular AMD, visual impairment due to DME, visual impairment due to macular oedema secondary to RVO and visual impairment due to CNV (see section&nbsp;4.2 for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Following monthly intravitreal administration of Lucentis to patients with neovascular AMD, serum concentrations of ranibizumab were generally low, with maximum levels (C<sub>max</sub>) generally below the ranibizumab concentration necessary to inhibit the biological activity of VEGF by 50% (11‑27&nbsp;ng/ml, as assessed in an <em>in vitro</em> cellular proliferation assay). C<sub>max</sub> was dose proportional over the dose range of 0.05 to 1.0&nbsp;mg/eye. Serum concentrations in a limited number of DME patients indicate that a slightly higher systemic exposure cannot be excluded compared to those observed in neovascular AMD patients. Serum ranibizumab concentrations in RVO patients were similar or slightly higher compared to those observed in neovascular AMD patients.</p><p>&nbsp;</p><p>Based on analysis of population pharmacokinetics and disappearance of ranibizumab from serum for patients with neovascular AMD treated with the 0.5&nbsp;mg dose, the average vitreous elimination half-life of ranibizumab is approximately 9&nbsp;days. Upon monthly intravitreal administration of Lucentis 0.5&nbsp;mg/eye, serum ranibizumab C<sub>max</sub>, attained approximately 1&nbsp;day after dosing, is predicted to generally range between 0.79 and 2.90&nbsp;ng/ml, and C<sub>min</sub> is predicted to generally range between 0.07 and 0.49&nbsp;ng/ml. Serum ranibizumab concentrations are predicted to be approximately 90,000‑fold lower than vitreal ranibizumab concentrations.</p><p>&nbsp;</p><p>Patients with renal impairment: No formal studies have been conducted to examine the pharmacokinetics of Lucentis in patients with renal impairment. In a population pharmacokinetic analysis of neovascular AMD patients, 68% (136 of 200) of patients had renal impairment (46.5% mild [50‑80&nbsp;ml/min], 20% moderate [30‑50&nbsp;ml/min], and 1.5% severe [&lt;30&nbsp;ml/min]). In RVO patients, 48.2% (253 of 525) had renal impairment (36.4% mild, 9.5% moderate and 2.3% severe). Systemic clearance was slightly lower, but this was not clinically significant.</p><p>&nbsp;</p><p>Hepatic impairment: No formal studies have been conducted to examine the pharmacokinetics of Lucentis in patients with hepatic impairment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Bilateral intravitreal administration of ranibizumab to cynomolgus monkeys at doses between 0.25&nbsp;mg/eye and 2.0&nbsp;mg/eye once every 2&nbsp;weeks for up to 26&nbsp;weeks resulted in dose-dependent ocular effects.</p><p>&nbsp;</p><p>Intraocularly, there were dose-dependent increases in anterior chamber flare and cells with a peak 2&nbsp;days after injection. The severity of the inflammatory response generally diminished with subsequent injections or during recovery. In the posterior segment, there were vitreal cell infiltration and floaters, which also tended to be dose-dependent and generally persisted to the end of the treatment period. In the 26‑week study, the severity of the vitreous inflammation increased with the number of injections. However, evidence of reversibility was observed after recovery. The nature and timing of the posterior segment inflammation is suggestive of an immune-mediated antibody response, which may be clinically irrelevant. Cataract formation was observed in some animals after a relatively long period of intense inflammation, suggesting that the lens changes were secondary to severe inflammation. A transient increase in post-dose intraocular pressure was observed following intravitreal injections, irrespective of dose.</p><p>&nbsp;</p><p>Microscopic ocular changes were related to inflammation and did not indicate degenerative processes. Granulomatous inflammatory changes were noted in the optic disc of some eyes. These posterior segment changes diminished, and in some instances resolved, during the recovery period.</p><p>&nbsp;</p><p>Following intravitreal administration, no signs of systemic toxicity were detected. Serum and vitreous antibodies to ranibizumab were found in a subset of treated animals.</p><p>&nbsp;</p><p>No carcinogenicity or mutagenicity data are available.</p><p>&nbsp;</p><p>In pregnant monkeys, intravitreal ranibizumab treatment resulting in maximal systemic exposures 0.9‑7‑fold a worst case clinical exposure did not elicit developmental toxicity or teratogenicity, and had no effect on weight or structure of the placenta, although, based on its pharmacological effect ranibizumab should be regarded as potentially teratogenic and embryo-/foetotoxic.</p><p>&nbsp;</p><p>The absence of ranibizumab-mediated effects on embryo-foetal development is plausibly related mainly to the inability of the Fab fragment to cross the placenta. Nevertheless, a case was described with high maternal ranibizumab serum levels and presence of ranibizumab in foetal serum, suggesting that the anti-ranibizumab antibody acted as (Fc region containing) carrier protein for ranibizumab, thereby decreasing its maternal serum clearance and enabling its placental transfer. As the embryo-foetal development investigations were performed in healthy pregnant animals and disease (such as diabetes) may modify the permeability of the placenta towards a Fab fragment, the study should be interpreted with caution.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&alpha;,&alpha;-trehalose dihydrate</p><p>Histidine hydrochloride, monohydrate</p><p>Histidine</p><p>Polysorbate 20</p><p>Water for injections</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&deg;C - 8&deg;C).</p><p>Do not freeze.</p><p>Keep the vial in the outer carton in order to protect from light.</p><p>Prior to use, the unopened vial may be kept at room temperature (25&deg;C) for up to 24&nbsp;hours.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Vial-only pack</u></p><p>&nbsp;</p><p>One vial (type I glass) with a stopper (chlorobutyl rubber) containing 0.23&nbsp;ml sterile solution.</p><p>&nbsp;</p><p><u>Vial + filter needle pack</u></p><p>&nbsp;</p><p>One vial (type I glass) with a stopper (chlorobutyl rubber) containing 0.23&nbsp;ml sterile solution and 1&nbsp;blunt filter needle (18G&nbsp;x&nbsp;1&frac12;&Prime;, 1.2&nbsp;mm&nbsp;x&nbsp;40&nbsp;mm, 5&nbsp;&micro;m).</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Vial + injection kit</u></p><p>&nbsp;</p><p>The vial, injection needle, filter needle and syringe are for single use only. Re-use may lead to infection or other illness/injury. All components are sterile. Any component with packaging showing signs of damage or tampering must not be used. The sterility cannot be guaranteed unless the component packaging seal remains intact.</p><p>&nbsp;</p><p><u>Vial + filter needle pack</u></p><p>&nbsp;</p><p>The vial and filter needle are for single use only. Re-use may lead to infection or other illness/injury. All components are sterile. Any component with packaging showing signs of damage or tampering must not be used. The sterility cannot be guaranteed unless the component packaging seal remains intact.</p><p>&nbsp;</p><p>For preparation and intravitreal injection the following medical devices for single use are needed:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a 5&nbsp;&micro;m filter needle (18G&nbsp;x&nbsp;1&frac12;&Prime;, 1.2&nbsp;mm&nbsp;x&nbsp;40&nbsp;mm, provided)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a 1&nbsp;ml sterile syringe (including a 0.05&nbsp;ml mark, not included within this pack)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an injection needle (30G&nbsp;x&nbsp;&frac12;&Prime;; not included within this pack)</p><p>&nbsp;</p><p>To prepare Lucentis for intravitreal administration, please adhere to the following instructions:</p><p>&nbsp;</p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Before withdrawal, the outer part of the rubber stopper of the vial should be disinfected.</p><p>&nbsp;</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Assemble a 5&nbsp;&micro;m filter needle (18G&nbsp;x&nbsp;1&frac12;&Prime;, 1.2&nbsp;mm&nbsp;x&nbsp;40&nbsp;mm) onto a 1&nbsp;ml syringe using aseptic technique. Push the blunt filter needle into the centre of the vial stopper until the needle touches the bottom edge of the vial.</p><p>&nbsp;</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Withdraw all the liquid from the vial, keeping the vial in an upright position, slightly inclined to ease complete withdrawal.</p><p>&nbsp;</p><p>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ensure that the plunger rod is drawn sufficiently back when emptying the vial in order to completely empty the filter needle.</p><p>&nbsp;</p><p>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Leave the blunt filter needle in the vial and disconnect the syringe from the blunt filter needle. The filter needle should be discarded after withdrawal of the vial contents and should not be used for the intravitreal injection.</p><p>&nbsp;</p><p>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Aseptically and firmly assemble an injection needle (30G&nbsp;x&nbsp;&frac12;&Prime;, 0.3&nbsp;mm&nbsp;x&nbsp;13&nbsp;mm) onto the syringe.</p><p>&nbsp;</p><p>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Carefully remove the cap from the injection needle without disconnecting the injection needle from the syringe.</p><p>&nbsp;</p><p>Note: Grip at the hub of the injection needle while removing the cap.</p><p>&nbsp;</p><p>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Carefully expel the air along with the excess solution and adjust the dose to the 0.05&nbsp;ml mark on the syringe. The syringe is ready for injection.</p><p>&nbsp;</p><p>Note: Do not wipe the injection needle. Do not pull back on the plunger.</p><p>&nbsp;</p><p>After injection, do not recap the needle or detach it from the syringe. Dispose of the used syringe together with the needle in a sharps disposal container or in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The Marketing Authorization Holder for this Product is Novartis Pharma AG. 
www.Novartis.com 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                10/2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>